Bruker Shares Continue to Be Buoyed by Laukien’s 200,000 Share Purchase

The share price of Bruker BioScience improved 6 percent over a six-day coverage period for the BioCommerce Week Index, closing Monday at $33.92, continuing a gain ignited largely by the insider purchase of 200,000 Bruker shares by CEO Frank Laukien.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.